Trispecific antibodies that include IL-15 have demonstrated the ability to enhance natural killer and T-cell proliferation, while tumor-localized IL-2 delivery helps activate immune cells directly at the tumor site with minimal systemic side effects. The gene discussed is IL2; the disease is neoplasm.